It remains unclear whether antipsychotic polypharmacy, a common clinical practice, is related to an increased risk of corrected time between start of Q wave and end of T wave (QTc) interval prolongation. We conducted a systematic review of the literature to address this important issue.
Method:
A systematic literature search was conducted in October 2014, using MEDLINE, Embase, and PsycINFO. Studies and case reports were included if they reported QTc intervals or QTc interval changes before and after antipsychotic polypharmacy or QTc intervals in both antipsychotic polypharmacy and monotherapy groups.
Results:
A total of 21 articles (10 clinical trials, 4 observational studies, and 7 case reports) met inclusion criteria. The clinical trials have shown that a combination treatment with risperidone or pimozide is not obviously related to an increase in QTc interval, whereas ziprasidone or sertindole combined with clozapine may prolong QTc interval. Among the 4 observational studies, antipsychotic polypharmacy was not clearly associated with QTc prolongation in 3 studies, each cross-sectional. In contrast, one prospective study showed a significant increase in QTc interval following antipsychotic coadministration. The case reports indicated an increased risk of QTc prolongation in at least some patients receiving antipsychotic polypharmacy.
Conclusions:
Currently available evidence fails to confirm that antipsychotic polypharmacy worsens QTc prolongation in general, although the evidence is scarce and inconsistent. Clinicians are advised to remain conservative in resorting to antipsychotic polypharmacy, as a combination of some QTc-prolongation liable antipsychotics may further prolong QTc interval, and efficacy supporting the clinical benefits of antipsychotic polypharmacy is equivocal, at best.
LeuchtSCiprianiASpineliLComparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis. Lancet. 2013;382(9896):951–962.
2.
HasnainMViewegW.QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: A comprehensive review. CNS Drugs. 2014;28(10):887–920.
KongsamutSKangJChenXLA comparison of the receptor binding and hERG channel affinities for a series of antipsychotic drugs. Eur J Pharmacol. 2002;450(1):37–41.
5.
TitierKCanalMDéridetEDetermination of myocardium to plasma concentration ratios of five antipsychotic drugs: Comparison with their ability to induce arrhythmia and sudden death in clinical practice. Toxicol Appl Pharmacol. 2004;199(1):52–60.
6.
MalikMFärbomPBatchvarovVRelation between QT and RR intervals is highly individual among healthy subjects: Implications for heart rate correction of the QT interval. Heart. 2002;87(3):220–228.
7.
MossAJ. Measurement of the QT interval and the risk associated with QTc interval prolongation: A review. Am J Cardiol. 1993;72(6):23B–25B.
8.
ZhangYPostWSBlasco-ColmenaresEElectrocardiographic QT interval and mortality: A meta-analysis. Epidemiology. 2011;22(5):660–670.
9.
Van NoordCSturkenboomMCStrausSMNon-cardiovascular drugs that inhibit hERG-encoded potassium channels and risk of sudden cardiac death. Heart. 2011;97(3):215–220.
10.
GallegoJABonettiJZhangJPrevalence and correlates of antipsychotic polypharmacy: A systematic review and metaregression of global and regional trends from the 1970s to 2009. Schizophr Res. 2012;138(1):18–28.
11.
SommerIEBegemannMJTemmermanAPharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: A quantitative literature review. Schizophr Bull. 2012;38(5):1003–1011.
12.
TaylorDMSmithLGeeSHAugmentation of clozapine with a second antipsychotic—a meta-analysis. Acta Psychiatr Scand. 2012;125(1):15–24.
13.
VeermanSRSchultePFBegemannMJNon-glutamatergic clozapine augmentation strategies: A review and meta-analysis. Pharmacopsychiatry. 2014;47(7):231–238.
14.
MoherDLiberatiATetzlaffJPreferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. BMJ. 2009;339:b2535. doi: 10.1136/bmj.b2535.
15.
CorrellCURummel-KlugeCCorvesCAntipsychotic combinations vs monotherapy in schizophrenia: A meta-analysis of randomized controlled trials. Schizophr Bull. 2009;35(2):443–457.
16.
YagciogluAE AnilAkdedeBB KivircikTurgutTIA double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: Efficacy and safety. J Clin Psychiatry. 2005;66(1):63–72.
17.
ZiegenbeinMKroppSKuenzelHE. Combination of clozapine and ziprasidone in treatment-resistant schizophrenia: An open clinical study. Clin Neuropharmacol. 2005;28(5):220–224.
18.
ChangJSAhnYMParkHJAripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: An 8-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2008;69(5):720–731.
19.
ZinkMKuwilskyAKrummBEfficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: A randomised controlled clinical trial. J Psychopharmacol. 2009;23(3):305–314.
20.
HendersonDCFanXCopelandPMZiprasidone as an adjuvant for clozapine- or olanzapine-associated medical morbidity in chronic schizophrenia. Hum Psychopharmacol. 2009;24(3):225–232.
21.
LinCHKuoCCChouLSA randomized, double-blind comparison of risperidone versus low-dose risperidone plus low-dose haloperidol in treating schizophrenia. J Clin Psychopharmacol. 2010;30(5):518–525.
22.
FriedmanJILindenmayerJPAlcantaraFPimozide augmentation of clozapine inpatients with schizophrenia and schizoaffective disorder unresponsive to clozapine monotherapy. Neuropsychopharmacology. 2011;36(6):1289–1295.
23.
NielsenJEmborgCGydesenSAugmenting clozapine with sertindole: A double-blind, randomized, placebo-controlled study. J Clin Psychopharmacol. 2012;32(2):173–178.
24.
Gunduz-BruceHOliverSGueorguievaREfficacy of pimozide augmentation for clozapine partial responders with schizophrenia. Schizophr Res. 2013;143(2–3):344–347.
25.
MuscatelloMRPandolfoGMicòUAugmentation of clozapine with ziprasidone in refractory schizophrenia: A double-blind, placebo-controlled study. J Clin Psychopharmacol. 2014;34(1):129–133.
26.
MackinPYoungAH. QTc interval measurement and metabolic parameters in psychiatric patients taking typical or atypical antipsychotic drugs: A preliminary study. J Clin Psychiatry. 2005;66(11):1386–1391.
27.
CorrellCUFredericksonAMFigenVThe QTc interval and its dispersion in patients receiving two atypical antipsychotics. Eur Arch Psychiatry Clin Neurosci. 2009;259(1):23–27.
28.
Ramos-RíosRArrojo-RomeroMPaz-SilvaEQTc interval in a sample of long-term schizophrenia inpatients. Schizophr Res. 2010;116(1):35–43.
29.
Di SciascioGCaloSAmodioGThe use of first generation versus second generation antipsychotics as add-on or as switch treatment and its effect on QTC interval: The Italian experience in a real-world setting. Int J Immunopathol Pharmacol. 2011;24(1):225–230.
30.
GurovichIVempatyALippmannS.QTc prolongation: Chlorpromazine and high-dosage olanzapine. Can J Psychiatry. 2003;48(5):348.
31.
NandagopalJJCraigJMLippmannS.QTc prolongation: Possible association with risperidone and/or haloperidol. Psychosomatics. 2003;44(6):521.
32.
LeoRRazziniCDi LorenzoGAsymptomatic QTc prolongation during coadministration of aripiprazole and haloperidol. J Clin Psychiatry. 2008;69(2):327–328.
33.
LinYSunIWLiuSIQTc prolongation during concurrent treatment with depot antipsychotics and high-dose amisulpride: A report of 2 cases. J Intern Med Taiwan. 2009;20(6):544–549.
34.
HanischFFriedemannJPillmannF.Combined treatment with quetiapine and sertindole in therapy refractory insomnia after clozapine discontinuation. J Psychopharmacol. 2010;24(11):1725–1726.
35.
EsslingerCIntaDEnglischSClozapine combined with paliperidone observations in schizophrenic patients with insufficient responses to clozapine monotherapy. German J Psychiatry. 2010;13:37–40.
36.
DhillonRBastiampillaiTTeeKClozapine and associated QTc prolongation. Aust N Z J Psychiatry. 2011;45(12):1098–1099.
37.
GallegoJANielsenJDe HertMSafety and tolerability of antipsychotic polypharmacy. Expert Opin Drug Saf. 2012;11(4):527–542.
38.
GoldenbergIMossAJZarebaW.QT interval: How to measure it and what is “normal.”J Cardiovasc Electrophysiol. 2006;17(3):333–336.
39.
PrioriSGSchwartzPJNapolitanoCRisk stratification in the long-QT syndrome. N Engl J Med. 2003;348(19):1866–1874.
TrinkleyKEPageRLLienHQT interval prolongation and the risk of torsades de pointes: Essentials for clinicians. Curr Med Res Opin. 2013;29(12):1719–1726.
42.
De YangFWangXQLiuXPSex difference in QTc prolongation in chronic institutionalized patients with schizophrenia on long-term treatment with typical and atypical antipsychotics. Psychopharmacology (Berl). 2011;216(1):9–16.
43.
StromBLEngSMFaichGComparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC). Am J Psychiatry. 2011;168(2):193–201.
44.
SugiyamaA.Sensitive and reliable proarrhythmia in vivo animal models for predicting drug-induced torsades de pointes in patients with remodelled hearts. Br J Pharmacol. 2008;154(7):1528–1537.
45.
FleischhackerWWUchidaH.Critical review of antipsychotic polypharmacy in the treatment of schizophrenia. Int J Neuropsychopharmacol. 2014;17(7):1083–1093.
